Co-founder and Board Chair David J. Bearss, Ph.D., has over 20 years of experience in small-molecule drug development, cell biology, and translational research focused on genetic markers and modeling systems to predict drug sensitivity. David’s passion for drug discovery and development stems from the loss of his grandfather and mother to colon cancer, and to this day, it still motivates him to create new medicines. David is joined by co-founder and CSO Hari Vankayalapati, M.Pharm, Ph.D., a trained medicinal and organic chemist and the author of over 70 publications. Together, the team at MolecuLern boasts over 100 patents, filed over a dozen INDs, has been involved in hundreds of clinical trials, and has achieved significant exits from previous companies.

The product of over two decades of work, Moleculern combines a deep understanding of biology and chemistry with the power of modern technology. This includes cutting-edge computational tools and machine learning AI, which are revolutionizing the drug discovery process. MolecuLern leverages these tools to streamline the traditional trial-and-error methods that have dominated the field for centuries. Drs. Bearrs and Vankayalapati are pioneers in this field, having been among the first to utilize computational techniques for drug discovery.

Advantages include: 

• AI Learning from Experience: MolecuLern trains its machine-learning models with decades of drug development knowledge, including successes and failures. This allows the AI to identify patterns and solve complex pharmacological problems.
• Massive Chemical Library: MolecuLern has a vast library of over five billion potential drug designs, including diverse options like small molecules and peptides.

• MolecuLern tackles complex challenges in drug development. This proprietary machine-learning algorithm and extensive compound library accelerate the process by solving pharmacological problems traditionally handled through lengthy research.
• MolecuLern cuts years off development timelines.  Two examples of faster delivery include drugs targeting obesity and metabolic syndrome, developed in 2023 and are expected to enter clinical trials by early 2025.
• Empowering companies with a robust preclinical pipeline with real-world applications. Companies other potential drugs will soon be ready for out-licensing or partnerships, indicating a strong future pipeline. Several promising partnerships are currently under discussion.